Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males

Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular... SummaryThis is the first study to report both greater BMD loss and muscle loss in Chinese HIV-infected males with lamivudine (3TC)-tenofovir disoproxil fumarate (TDF)-efavirenz (EFV) regimen, which highlights the importance of closely monitoring muscle mass and bone mineral density in patients treated with 3TC-TDF-EFV regimen and provides a foundation for the clinical intervention of sarcopenia and osteoporosis.PurposeTo compare the effect initiating different antiretroviral therapy (ART) regimens have on muscle mass, bone mineral density (BMD), and trabecular bone score (TBS).MethodsWe designed a retrospective study of ART-naive Chinese males with HIV (MWH) undergoing two different regimens at 1-year follow-up. All subjects underwent dual-energy absorptiometry (DXA) for BMD and muscle mass prior to ART initiation, and again 1 year later. TBS iNsight software was used for TBS. We analyzed differences in muscle mass, BMD, and TBS after different treatment arms and associations between ART regimens and changes in them.ResultsA total of 76 men were included (mean age 31.83 ± 8.75 years). Mean absolute muscle mass decreased significantly from baseline to follow-up after initiation of lamivudine (3TC)-tenofovir disoproxil fumarate (TDF)-efavirenz (EFV), whereas increased significantly after initiation of 3TC-zidovudine(AZT)/Stavudine(d4T)-Nevirapine(NVP). Assignment to 3TC-TDF-EFV resulted in greater percentage loss in BMD at lumbar spine (LS) and total hip (TH) compared to 3TC-AZT/d4T-NVP, but this difference was not statistically significant at the femoral neck BMD and TBS. In the multivariable logistic regression model adjusted for covariates, the 3TC-TDF-EFV regimen was associated with higher odds of decreased appendicular and total muscle mass, LS and TH BMD.ConclusionsThis is the first study to report not only greater BMD loss but also muscle loss in Chinese MWH with 3TC-TDF-EFV regimen. Our work highlights the importance of closely monitoring muscle mass and BMD in patients treated with 3TC-TDF-EFV regimen and provides a foundation for the clinical intervention of sarcopenia and osteoporosis in them. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Osteoporosis Springer Journals

Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/effect-of-different-antiretroviral-therapy-on-muscle-mass-bone-mineral-7RQ24RFgJh
Publisher
Springer Journals
Copyright
Copyright © International Osteoporosis Foundation and Bone Health and Osteoporosis Foundation 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
ISSN
1862-3522
eISSN
1862-3514
DOI
10.1007/s11657-023-01238-6
Publisher site
See Article on Publisher Site

Abstract

SummaryThis is the first study to report both greater BMD loss and muscle loss in Chinese HIV-infected males with lamivudine (3TC)-tenofovir disoproxil fumarate (TDF)-efavirenz (EFV) regimen, which highlights the importance of closely monitoring muscle mass and bone mineral density in patients treated with 3TC-TDF-EFV regimen and provides a foundation for the clinical intervention of sarcopenia and osteoporosis.PurposeTo compare the effect initiating different antiretroviral therapy (ART) regimens have on muscle mass, bone mineral density (BMD), and trabecular bone score (TBS).MethodsWe designed a retrospective study of ART-naive Chinese males with HIV (MWH) undergoing two different regimens at 1-year follow-up. All subjects underwent dual-energy absorptiometry (DXA) for BMD and muscle mass prior to ART initiation, and again 1 year later. TBS iNsight software was used for TBS. We analyzed differences in muscle mass, BMD, and TBS after different treatment arms and associations between ART regimens and changes in them.ResultsA total of 76 men were included (mean age 31.83 ± 8.75 years). Mean absolute muscle mass decreased significantly from baseline to follow-up after initiation of lamivudine (3TC)-tenofovir disoproxil fumarate (TDF)-efavirenz (EFV), whereas increased significantly after initiation of 3TC-zidovudine(AZT)/Stavudine(d4T)-Nevirapine(NVP). Assignment to 3TC-TDF-EFV resulted in greater percentage loss in BMD at lumbar spine (LS) and total hip (TH) compared to 3TC-AZT/d4T-NVP, but this difference was not statistically significant at the femoral neck BMD and TBS. In the multivariable logistic regression model adjusted for covariates, the 3TC-TDF-EFV regimen was associated with higher odds of decreased appendicular and total muscle mass, LS and TH BMD.ConclusionsThis is the first study to report not only greater BMD loss but also muscle loss in Chinese MWH with 3TC-TDF-EFV regimen. Our work highlights the importance of closely monitoring muscle mass and BMD in patients treated with 3TC-TDF-EFV regimen and provides a foundation for the clinical intervention of sarcopenia and osteoporosis in them.

Journal

Archives of Osteoporosis – Springer Journals

Published: Apr 11, 2023

Keywords: Human immunodeficiency virus (HIV); Antiretroviral therapy (ART); Muscle mass; Bone mineral density (BMD); Trabecular bone score (TBS)

References

  • Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV Outpatient Study Investigators
    Palella, FJ; Delaney, KM; Moorman, AC
  • Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors
    Goh, SSL; Lai, PSM; Tan, ATB
  • Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
    Sax, PE; Wohl, D; Yin, MT
  • Sarcopenia in people living with the human immunodeficiency virus: a systematic review and meta-analysis
    Oliveira, VHF; Borsari, AL; Webel, AR
  • Sarcopenia among people living with HIV and the effect of antiretroviral therapy on body composition
    Konishi, K; Nakagawa, H; Asaoka, T
  • People Living With HIV, Lean mass, and sarcopenia: a systematic review and meta-analysis
    Guimarães, NS; Raposo, MA; Greco, D
  • High prevalence of sarcopenia in HIV-infected individuals
    Echeverría, P; Bonjoch, A; Puig, J
  • Assessment of sarcopenia in virally suppressed HIV-infected Asians receiving treatment
    Abdul Aziz, SA; McStea, M; Ahmad Bashah, NS
  • Longitudinal change in bone mineral density among Chinese individuals with HIV after initiation of antiretroviral therapy
    Guo, F; Song, X; Li, Y
  • Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials
    Tao, X; Lu, Y; Zhou, Y
  • Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study
    Stellbrink, HJ; Orkin, C; Arribas, JR
  • Changes in trabecular bone score and bone mineral density in Chinese HIV-Infected individuals after one year of antiretroviral therapy
    Guan, WM; Pan, W; Yu, W
  • Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202
    McComsey, GA; Kitch, D; Daar, ES
  • Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women
    McDermott, AY; Shevitz, A; Knox, T
  • Regional anthropometry changes in antiretroviral-naïve persons initiating a Zidovudine-containing regimen in Mbarara
    Thompson, V; Medard, B; Taseera, K
  • Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy
    Dubé, MP; Qian, D; Edmondson-Melançon, H
  • Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy
    Mallon, PW; Miller, J; Cooper, DA
  • Changes in weight and lean body mass during highly active antiretroviral therapy
    Shikuma, CM; Zackin, R; Sattler, F
  • Effects of 96 weeks of rosuvastatin on bone, muscle, and fat in HIV-infected adults on effective antiretroviral therapy
    Erlandson, KM; Jiang, Y; Debanne, SM
  • Expansion of Chinaʼs free antiretroviral treatment program
    Zhao, DC; Wen, Y; Ma, Y
  • Long-term trabecular bone score and bone mineral density changes in Chinese antiretroviral-treated HIV-infected individuals
    Guan, W; Pan, W; Yu, W
  • Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment
    Chen, LK; Woo, J; Assantachai, P
  • International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions
    Lewiecki, EM; Gordon, CM; Baim, S
  • Trabecular bone score: a noninvasive analytical method based upon the DXA image Journal of bone and mineral research : the official
    Silva, BC; Leslie, WD; Resch, H
  • Dolutegravir plus two different prodrugs of tenofovir to treat HIV
    Venter, WDF; Moorhouse, M; Sokhela, S
  • Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial
    Venter, WDF; Sokhela, S; Simmons, B
  • Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density
    Erlandson, KM; Kitch, D; Tierney, C
  • Metabolic effects of preexposure prophylaxis with coformulated tenofovir disoproxil fumarate and emtricitabine
    Glidden, DV; Mulligan, K; McMahan, V
  • Immediate initiation of antiretroviral therapy for HIV infection accelerates bone loss relative to deferring therapy: findings from the START Bone Mineral Density Substudy, a randomized trial Journal of bone and mineral research : the official
    Hoy, JF; Grund, B; Roediger, M
  • A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX Journal of bone and mineral research : the official
    McCloskey, EV; Odén, A; Harvey, NC
  • Assessment of trabecular bone score, an index of bone microarchitecture, in HIV positive and HIV negative persons within the HIV UPBEAT cohort
    McGinty, T; Cotter, AG; Sabin, CA
  • Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation
    Grant, PM; Kitch, D; McComsey, GA
  • Role of T-cell reconstitution in HIV-1 antiretroviral therapy-induced bone loss
    Ofotokun, I; Titanji, K; Vikulina, T
  • CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study
    McDermott, AY; Terrin, N; Wanke, C